FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283271473> ?p ?o ?g. }

• W4283271473 endingPage "190" @default.
• W4283271473 startingPage "181" @default.
• W4283271473 abstract "Objective: Ixekizumab is a high-affinity monoclonal antibody that selectively targets interleukin-17A and is approved for treating moderate-to-severe psoriasis. This phase 3, multicenter, randomized, double-blind, placebo-controlled trial (NCT03364309; registered December 6, 2017) evaluated the safety and efficacy of ixekizumab in Chinese patients with moderate-to-severe psoriasis. Methods: 438 patients were randomized 2:2:1 to 80 mg ixekizumab every 2 weeks (IXE Q2W, n = 176), 80 mg ixekizumab every 4 weeks (IXE Q4W, n = 174), or placebo ( n = 88). Efficacy was assessed by evaluating the static Physician’s Global Assessment score of 0 or 1 (sPGA [0,1]) and Psoriasis Area and Severity Index (PASI) 75/90/100 responses, and nonresponder imputation was used for handling missing data. The safety profile was evaluated by assessing treatment emergent adverse events (AEs) and serious AEs. Results: At week 12, the sPGA (0,1) response rates were 3.4%, 79.9%, and 86.4% in the placebo, IXE Q4W, and IXE Q2W groups, respectively. The PASI 75/90/100 response rates were 8.0%/2.3%/0.0%, 87.4%/75.9%/29.3%, and 93.8%/82.4%/33.0% in the placebo, IXE Q4W, and IXE Q2W groups, respectively. Ixekizumab led to rapid PASI 50 responses, as early as week 1, whereas PASI 75 and sPGA (0,1) responses were observed from week 2. sPGA (0,1) and sPGA (0) responses were maintained through week 60 in a higher proportion of patients receiving IXE Q4W vs. placebo. The safety profile was consistent with previous studies of ixekizumab in psoriasis. Conclusion: Ixekizumab showed a rapid onset of action and high efficacy that was maintained through 60 weeks and was well tolerated with no unexpected AEs, in Chinese patients with moderate-to-severe plaque psoriasis." @default.
• W4283271473 created "2022-06-23" @default.
• W4283271473 creator A5004274288 @default.
• W4283271473 creator A5011747309 @default.
• W4283271473 creator A5023283416 @default.
• W4283271473 creator A5034096658 @default.
• W4283271473 creator A5058637559 @default.
• W4283271473 creator A5063488503 @default.
• W4283271473 creator A5075641310 @default.
• W4283271473 creator A5077063251 @default.
• W4283271473 creator A5079738340 @default.
• W4283271473 creator A5082921671 @default.
• W4283271473 date "2022-06-21" @default.
• W4283271473 modified "2023-10-16" @default.
• W4283271473 title "Efficacy and Safety of Ixekizumab in Chinese Patients With Moderate-to-Severe Plaque Psoriasis: 60-Week Results From a Phase 3 Study" @default.
• W4283271473 cites W2046680359 @default.
• W4283271473 cites W2084943874 @default.
• W4283271473 cites W2121126920 @default.
• W4283271473 cites W2171889601 @default.
• W4283271473 cites W2217326824 @default.
• W4283271473 cites W2418506270 @default.
• W4283271473 cites W2470846004 @default.
• W4283271473 cites W2551958233 @default.
• W4283271473 cites W2625791318 @default.
• W4283271473 cites W2791445230 @default.
• W4283271473 cites W2901986848 @default.
• W4283271473 cites W2912058252 @default.
• W4283271473 cites W2941146433 @default.
• W4283271473 cites W2980508062 @default.
• W4283271473 cites W2998319702 @default.
• W4283271473 cites W3029724060 @default.
• W4283271473 cites W3084613618 @default.
• W4283271473 doi "https://doi.org/10.1097/jd9.0000000000000244" @default.
• W4283271473 hasPublicationYear "2022" @default.
• W4283271473 type Work @default.
• W4283271473 citedByCount "3" @default.
• W4283271473 countsByYear W42832714732022 @default.
• W4283271473 countsByYear W42832714732023 @default.
• W4283271473 crossrefType "journal-article" @default.
• W4283271473 hasAuthorship W4283271473A5004274288 @default.
• W4283271473 hasAuthorship W4283271473A5011747309 @default.
• W4283271473 hasAuthorship W4283271473A5023283416 @default.
• W4283271473 hasAuthorship W4283271473A5034096658 @default.
• W4283271473 hasAuthorship W4283271473A5058637559 @default.
• W4283271473 hasAuthorship W4283271473A5063488503 @default.
• W4283271473 hasAuthorship W4283271473A5075641310 @default.
• W4283271473 hasAuthorship W4283271473A5077063251 @default.
• W4283271473 hasAuthorship W4283271473A5079738340 @default.
• W4283271473 hasAuthorship W4283271473A5082921671 @default.
• W4283271473 hasBestOaLocation W42832714731 @default.
• W4283271473 hasConcept C126322002 @default.
• W4283271473 hasConcept C142724271 @default.
• W4283271473 hasConcept C16005928 @default.
• W4283271473 hasConcept C197934379 @default.
• W4283271473 hasConcept C204787440 @default.
• W4283271473 hasConcept C27081682 @default.
• W4283271473 hasConcept C2776260265 @default.
• W4283271473 hasConcept C2777011040 @default.
• W4283271473 hasConcept C2779745271 @default.
• W4283271473 hasConcept C2779786854 @default.
• W4283271473 hasConcept C2780564577 @default.
• W4283271473 hasConcept C71924100 @default.
• W4283271473 hasConceptScore W4283271473C126322002 @default.
• W4283271473 hasConceptScore W4283271473C142724271 @default.
• W4283271473 hasConceptScore W4283271473C16005928 @default.
• W4283271473 hasConceptScore W4283271473C197934379 @default.
• W4283271473 hasConceptScore W4283271473C204787440 @default.
• W4283271473 hasConceptScore W4283271473C27081682 @default.
• W4283271473 hasConceptScore W4283271473C2776260265 @default.
• W4283271473 hasConceptScore W4283271473C2777011040 @default.
• W4283271473 hasConceptScore W4283271473C2779745271 @default.
• W4283271473 hasConceptScore W4283271473C2779786854 @default.
• W4283271473 hasConceptScore W4283271473C2780564577 @default.
• W4283271473 hasConceptScore W4283271473C71924100 @default.
• W4283271473 hasIssue "4" @default.
• W4283271473 hasLocation W42832714731 @default.
• W4283271473 hasOpenAccess W4283271473 @default.
• W4283271473 hasPrimaryLocation W42832714731 @default.
• W4283271473 hasRelatedWork W1998836331 @default.
• W4283271473 hasRelatedWork W2073564793 @default.
• W4283271473 hasRelatedWork W2752688736 @default.
• W4283271473 hasRelatedWork W2765893416 @default.
• W4283271473 hasRelatedWork W2898213950 @default.
• W4283271473 hasRelatedWork W3015166491 @default.
• W4283271473 hasRelatedWork W3084176453 @default.
• W4283271473 hasRelatedWork W3084613618 @default.
• W4283271473 hasRelatedWork W3193126242 @default.
• W4283271473 hasRelatedWork W4362460262 @default.
• W4283271473 hasVolume "5" @default.
• W4283271473 isParatext "false" @default.
• W4283271473 isRetracted "false" @default.
• W4283271473 workType "article" @default.